These 10 Hedge Fund Are Probably Really, Really Happy They Invested In Vivus

ken griffinCitadel’s Ken Griffin

Photo: Courtesy of Citadel

Shares of drugmaker Vivus skyrocketed today after an FDA panel gave a favourable review for the company’s weight loss pill.The stock was last up more than 88% in late morning trading.

That’s good news for a bunch of hedge fund managers who have a significant stake in Vivus. 

Here are the top 10 hedge funds with the biggest positions in the drugmaker, according to data compiled by Bloomberg.

1.  Chilton Investment: ~8.62 million shares (9.7%)

2. QVT Financial LP: ~8.53 million shares (9.59%)

3. OrbiMed Advisors: ~6.16 million shares (6.94%)

4.  Caxton Associates: ~5.25 million shares (5.91%)

5. Suttonbrook Capital: ~5.05 million shares (5.68%)

6.  Passport Capital: ~4.29 million shares (4.83%)

7.  Citadel Advisors: ~1.85 million shares (2.08%)

8.  Severn River Capital: ~ 1.29 million shares (1.45%)

9.  D.E. Shaw & Co.: 645,633 shares (0.73%)

10.  SAC Capital: 538,400 shares (0.61%)

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.